Common Genetic Variants of The Cardiac Sodium Channel Alter Patient Response to Class 1b Antiarrhythmics
Authors:
Preprint
Abstract
Several common variants have been identified in SCN5A, which encodes the cardiac sodium channel α-subunit Nav1.5 and is targeted by class I antiarrhythmics. Lidocaine and its analog mexiletine both have a primary amine that blocks Na + current. While lidocaine is highly effective in terminating ventricular tachycardia after acute myocardial infarction, mexiletine has been shown to prevent arrhythmia induction in only ∼20% of patients. The factors underlying this inconsistent drug response are unclear. Here, we use cardiomyocytes that are derived from induced pluripotent stem cells to observe that a common polymorphism in the SCN5A gene, S1103Y, exhibits an altered pharmacological response to mexiletine, with enhanced use-dependent and tonic block of peak sodium current. In addition, an unexpected increase in late sodium current causes action potential prolongation. This paradoxical proarrhythmic phenotype shifts the paradigm of conventional antiarrhythmic therapy with mexiletine, suggesting that background variants may alter pharmacological responses leading to unanticipated consequences. Our results suggest that the unique genetic background of patients should inform therapeutic approaches to treat and prevent arrhythmias associated with common cardiac pathologies.Keywords
All Related Versions
- Published version: The Journal of Precision Medicine: Health and Disease, 6.
Funding Information
- National Heart Lung and Blood Institutes of Health (R01 HL148803)
- American Heart Association (24PRE1198562)
- American Heart Association (960621)
This publication has 64 references indexed in Scilit:
- Characterizing fenestration size in sodium channel subtypes and their accessibility to inhibitorsBiophysical Journal, 2022
- Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statementAmerican Journal of Preventive Cardiology, 2021
- High-Throughput Reclassification of SCN5A VariantsThe American Journal of Human Genetics, 2020
- Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysisAnalytical Biochemistry, 2016
- Tetrodotoxin-sensitive α-subunits of voltage-gated sodium channels are relevant for inhibition of cardiac sodium currents by local anestheticsNaunyn-Schmiedeberg's Archives of Pharmacology, 2016
- Cardiac Na Channels2016
- Acid–base and electrolyte abnormalities in heart failure: pathophysiology and implicationsHeart Failure Reviews, 2015
- Mexiletine: Pharmacology and therapeutic useClinical Cardiology, 1990
- Comparison of intravenous mexiletine and lidocaine for the treatment of ventricular arrhythmiasAmerican Heart Journal, 1986
- Oral mexiletine in the treatment of refractory ventricular arrhythmias: The role of electrophysiologic techniquesAmerican Heart Journal, 1984